rmalla@gitam.edu
LinkedIn
Google Scholar
Scopus
ORCiD
Prof. Malla's lab at GITAM University is dedicated to fighting TNBC. Identified CD151 as a key target, diagnostic, and prognostic marker. Explored CD151's role in drug resistance, discovered novel inhibitors, and evaluated microRNAs for diagnosis. Developed BSA-based hydrogels for drug delivery, exploring CD151-derived peptides as vaccine candidates, studying immunogenic cell death. Prof. Malla envisions a cancer consortium and clinical trial on CD151 and CD151-targeting therapies.
Research Publications
- 1. Neoantigens as Promising Vaccine Candidates for Triple Negative Breast Cancer: Insights into different vaccine approaches and Nanodelivery Strategies. Journal of Controlled Release 370 (2024) 707–720. (Q1, IF: 10.8; HI:313) (Scopus). ISSN: 01683659, 18734995. 2. Messenger RNA Vaccines and their Delivery Strategies: A Journey from Infectious Diseases to Cancer. Molecular Therapy, November 2023, Nov 1:S1525-0016(23)00601-9, (Q1, IF: 12.4; HI:171) Scopus ISSN: 15250024, 15250016. 3. Proteomic profiling and ROC analysis identify CD151 and ELAVL1 as potential therapy response markers for the antiviral drug in resistant TNBC, Life Sciences, May 2022,320:121534. (Q1, IF: 6.78; HI:164) Scopus ISSN: 00243205.. 4. Insight into drug sensitizing effect of diallyl disulfide and diallyl trisulfide from Allium sativum L. on paclitaxel-resistant triple-negative breast cancer cells. Journal of Ethnopharmacology, April 2022, 296:115452. (Q1, IF: 5.195; HI:205) Scopus ISSN: 03788741. 5. HOTAIR: A potential metastatic, drug-resistant, and prognostic regulator of breast cancer. Molecular Cancer, March 2023, (Q1, IF: 34.44; HI:146) Scopus ISSN: 14764598. Mar 30;22(1):65. doi: 10.1186/s12943-023-01765-3
Ongoing Research Projects
-
1. Investigations on combinatorial effect of verteporfin and 2-thio-6-azauridine for sensitization of paclitaxel-resistant triple-negative breast cancer stem cells (CRG/2023/001951). (66.7 Lakhs). Funding Agency: DST-CRG, Feb 2024-27. 2. Exploring carbon ion radiotherapy for sensitization of CD151+ stem-like Paclitaxel resistant subpopulation of triple-negative breast cancer. Funding Agency: UGC-DAE-CSR, Kolkata. (9.5 Lakhs). 3. Molecular study on role of Triple Negative Breast Cancer Patient Derived CD151 Positive Serum Exosomes in Metastasis of breast cancer (Project No.2470). Funding Agency: Ministry of Education: April 2024 – 31st March 2026). (74.04 Lakhs). 4. Study on the evaluation of the photoprotective activity of marine actinobacterial derived melanin and its therapeutic applications. Mentor, (Rs. 32.74Lakhs).DST-WOS-A, to Dr Viswadeepika Kuchipudi, 2022-25.
Expertise
-
1. RNAi Technology & Molecular Biology - Design and construction of siRNA, shRNA and microRNA. PCR, RT-PCR, Real-Time PCR, FACS analysis, Western blotting, transfection. 2. Cancer Biology - Culture and maintenance of cancer cells, isolation of cancer stem cells, isolation and culturing of patient derived tumor cells. Cellular and Nuclear imaging, adhesion, invasion and migration, tissue processing and preparation of tumor sections, DNA analysis. Tumor microenvironment. 3. Immunological techniques - ELISA, Immunofluorescence, Immunoprecipitation, Chromatin immunoprecipitation, Immunodiffusion, immune-histochemical staining. 4. Animal Studies - Stereotactic implantation of brain cancer cells, Mouse mammary tumor pads. 5. Bio-databases - GENT, STRING, Expasy, SWISS-PROT, BLAST and FASTA. TIMER 2.0
Authored Books
-
1. A theranostic and precision medicine approaches for female specific cancers. 2020, Elsevier,
